Interventions of Interest: tirzepatide (Eli Lilly) More than 34 million Americans, or 10% of the US population, have diabetes mellitus. Type 2 diabetes mellitus (T2DM), which is characterized by progressive loss of adequate insulin secretion from the pancreas and peripheral resistance to insulin, accounts for 90-95% of those cases. Prevalence of T2DM increases with age […]
Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab) Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction. For more information, please contact Maggie O’Grady, Program Manager, at mogrady@icer.org. View the Key […]
Interventions of Interest: abrocitinib (Pfizer) tralokinumab (Adtralza®, LEO Pharma) baricitinib (Olumiant®, Eli Lilly, Incyte Corporation) upadacitinib (Rinvoq®, AbbVie) ruxolitinib (Opzelura™, Incyte Corporation) Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the […]
Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]
Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S). The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control […]
Recent Comments